Formulations for reducing neuronal degeneration

• US 8,173,618 B2
• Filed: 07/23/2004
• Issued: 05/08/2012
• Est. Priority Date: 07/25/2003
• Status: Active Grant

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Shea, Thomas B., Nicolosi, Robert J., Rogers, Eugene
• Primary Examiner(s): Padmanabhan, Sreeni
• Assistant Examiner(s): KAROL, JODY LYNN
• Application Number:
  US10/898,393
• Publication Number:
  US 20050043312A1
• Time in Patent Office: 2,846 Days
• Field of Search: 514/46, 514/263.3, 514/303, 514/562
• US Class Current: 514/46
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/0612 Carnitine
• CPC Class Codes: A23V 2250/704 Vitamin B
• CPC Class Codes: A23V 2250/712 Vitamin E
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/525 Isoalloxazines, e.g. riboflavins, vitamin B2
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Nutriceutical and pharmaceutical formulations for treating neurodegenerative disorders such as Alzheimer'"'"'s disease are provided. Nutriceutical formulations include two or more of folate, vitamin E, and acetyl-L-carnitine (ALCAR). Pharmaceutical formulations include two or more of 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM).

Claims

1. A composition comprising 3-deaza-adenosine (DZA), N-acetyl-L-cysteine (NAC), and S-adenosylmethionine (SAM) in combination or in individual dosage forms, wherein a unit dose of the composition reduces a level of reactive oxygen species (ROS) in an in vitro neural cell culture.

2. The composition of claim 1, further comprising at least one of folate, acetyl-L-carnitine (ALCAR), and vitamin E.

3. The composition of claim 1, further comprising at least two of folate, acetyl-L-carnitine (ALCAR), and vitamin E.

4. The composition of claim 1, further comprising folate, acetyl-L-carnitine (ALCAR), and vitamin E.

5. The composition of claim 4, wherein the composition comprises about 200-2000 μ

g folate, about 50-3000 I.U. vitamin E, and about 200-4000 mg acetyl-L-carnitine (ALCAR).

6. The composition of claim 2, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), and folate.

7. The composition of claim 2, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), and acetyl-L-carnitine (ALCAR).

8. The composition of claim 2, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), and vitamin E.

9. The composition of claim 3, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), folate, and acetyl-L-carnitine (ALCAR).

10. The composition of claim 3, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), folate, and vitamin E.

11. The composition of claim 3, wherein the composition comprises N-acetyl-L-cysteine (NAC), S-adenosylmethionine (SAM), 3-deaza-adenosine (DZA), acetyl-L-carnitine (ALCAR), and vitamin E.